Table 1 Clinical features of patients.

From: Efficacy and safety of immunosuppressive therapy versus cyclosporine combined with avatrombopag in older adults with severe aplastic anemia: a multicenter prospective study

Clinical features

All (N = 84)

ATG+CsA+AVA (n = 42)

CsA+AVA (n = 42)

P value

Median age (range), yrs

65 (60–84)

65.5 (60–78)

65 (60–84)

0.381

Male/female (n)

39/45

18/24

21/21

0.512

The median duration from diagnosis to treatment (days, range)

1.1 (0.2–35.8)

1 (0.3–30)

1.3 (0.2–35.8)

0.138

Severity classification, no. (%)

   

0.175

SAA

67 (79.8%)

31 (73.8%)

36 (85.7%)

 

VSAA

17 (20.2%)

11 (26.2%)

6 (14.3%)

 

HGB (g/L)

59 (25–82)

59 (33–82)

58 (25–79)

0.694

PLT (×1012/L)

7.5 (1–43)

6 (1–34)

8 (1–43)

0.119

WBC (×109/L)

2.01 (0.42–4.04)

2.12 (0.42–4.04)

2.01 (0.74–3.67)

0.947

ANC (×109/L)

0.54 (0.01–1.49)

0.46 (0.01–1.49)

0.63 (0.04–1.30)

0.153

Fer (μg/L)

903.5 (11–6409)

713.45 (165–4456.3)

1060.5 (11–6409)

0.195

PNH clone-positive, no. (%)

17 (20.2%)

11 (26.2%)

6 (14.3%)

0.175

PNH clone size (granulocyte flare, %)

6.5 (1.2–18)

3.8 (1.2–17.2)

7.75 (1.4–18)

0.451

Chromosomal karyotype abnormality, no. (%)

11 (13.1%)

5 (11.9%)

6 (14.3%)

0.746

-Y

3 (3.6%)

2 (4.8%)

1 (2.4%)

1.000

del(13)(q12q22)

2 (2.4%)

0 (0.0%)

2 (4.8%)

0.494

+Y

1 (1.2%)

1 (2.4%)

0 (0.0%)

1.000

+8

1 (1.2%)

1 (2.4%)

0 (0.0%)

1.000

+19

1 (1.2%)

0 (0.0%)

1 (2.4%)

1.000

-X

1 (1.2%)

0 (0.0%)

1 (2.4%)

1.000

9qh+

1 (1.2%)

0 (0.0%)

1 (2.4%)

1.000

t(8;11)(q24;p15)

1 (1.2%)

1 (2.4%)

0 (0.0%)

1.000

Myeloid gene mutation, no. (%)

23 (27.4%)

13 (31.0%)

10 (23.8%)

0.463

The median follow-up time (months, range)

13 (0.3–17)

13.3 (0.3–17)

13 (4.7–17)

0.872

  1. ATG antithymocyte globulin, CsA cyclosporine A, AVA avatrombopag, HGB hemoglobin, WBC white blood cell, PLT platelet, ANC absolute neutrophil count, Fer ferritin, PNH paroxysmal nocturnal hemoglobinuria.
Back to article page